Work

Supplementary Figures 1 - 3 from Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 1. Immunohistochemical analyses of tumors from NSCLC patient with FGFR2 A266_S267ins for H&E (hematoxylin and eosin) (A), and CD56 (B). Supplemental Figure 2. The signal inhibitory effect of ponatinib in cells expressing FGFR2 A266_S267ins, FGFR2 290_291WI>C or FGFR2-TACC3. Supplemental figure 3. The effect of FGF stimulation in NIH-3T3 cells with FGFR2 wild type and those with FGFR2 A266_S267ins.

DOI: 10.1158/0008-5472.22405188.v1

Authors: Junko Tanizaki, Dalia Ercan, Marzia Capelletti, Michael Dodge, Chunxiao Xu, Magda Bahcall, Erin M. Tricker, Mohit Butaney, Antonio Calles, Lynette M. Sholl, Peter S. Hammerman, Geoffrey R. Oxnard, Kwok-Kin Wong, Pasi A. Jänne

Language: English

Topic: Fibroblast Growth Factor Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361834008

Cites:

Cited by:

Related to: 10